| Active, not recruiting | 2 | 68 | US, RoW | Tomivosertib, eFT508, Pembrolizumab, Keytruda®, Pemetrexed, Alimta® | Effector Therapeutics, Medpace, Inc., ICON plc | Non-small Cell Lung Cancer | 10/24 | 12/24 | | |
NCT05744739: Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) |
|
|
| Active, not recruiting | 1 | 15 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Tomivosertib, EFT-508, eFT508, Spiro(cyclohexane-1,3'(2'H)-imidazo(1,5-a)pyridine)-1',5'-dione, 6'-((6-Amino-4-pyrimidinyl)amino)-8'-methyl- | Northwestern University, National Cancer Institute (NCI), EFFECTOR Therapeutics, Inc. | Acute Myeloid Leukemia | 04/29 | 04/30 | | |
